DCN and glioblastoma: Although decorin, biglycan and serglycin were found up regulated in GBM samples, only Decorin levels were negatively associated with GBM patient overall survival, suggesting Decorin as a putative microenvironmental glycomarkers/targets for GBM diagnostics and therapy (61).